Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Weinstein

Showing results (61-70 of 91) with videos related to

Pageof 10
Sort By:
Molecular Genetics and Metabolism|January 7, 2014
Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 geneDeeksha S Bali, Jennifer L Goldstein, Keri Fredrickson, et al.
American Journal of Obstetrics and Gynecology|February 5, 2008
Pregnancies in glycogen storage disease type IaDaniëlle H J Martens, Jan Peter Rake, Martin Schwarz, et al.
Hepatology Communications|November 9, 2019
Liver Glycogen Phosphorylase Deficiency Leads to Profibrogenic Phenotype in a Murine Model of Glycogen Storage Disease Type VILane H Wilson, Jun-Ho Cho, Ana Estrella, et al.
Journal of Inherited Metabolic Disease|May 27, 2018
Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type IaYoung Mok Lee, Thomas J Conlon, Andrew Specht, et al.
JIMD Reports|August 26, 2015
Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type IKatalin M Ross, Laurie M Brown, Michelle M Corrado, et al.
Journal of Inherited Metabolic Disease|August 16, 2019
Cornstarch requirements of the adult glycogen storage disease Ia population: A retrospective reviewKathryn R Dahlberg, Iris A Ferrecchia, Monika Dambska-Williams, et al.
Molecular Therapy. Methods & Clinical Development|September 16, 2024
Validation of high-sensitivity assays to quantitate cerebrospinal fluid and serum β-galactosidase activity in patients with GM1-gangliosidosisKaren J Quadrini, Catherine Vrentas, Christian Duke, et al.
Biochemical and Biophysical Research Communications|January 26, 2020
Glucose-6-phosphate transporter mediates macrophage proliferation and functions by regulating glycolysis and mitochondrial respirationEek Hyung Jeon, Tae Sub Park, Yuyeon Jang, et al.
Journal of Inherited Metabolic Disease|April 12, 2017
Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic controlFabian Peeks, Thomas A H Steunenberg, Foekje de Boer, et al.
Journal of Health Economics and Outcomes Research|February 16, 2026
Trial Interviews to Explore Glycogen Storage Disease Type Ia Patient Experiences Following Gene TherapyDiane M Turner-Bowker, Jessica Butler, Shayna Egan, et al.
Pageof 10

Showing results (61-70 of 91) with videos related to

Sort By:
Pageof 10
Molecular Genetics and Metabolism|January 7, 2014
Variability of disease spectrum in children with liver phosphorylase kinase deficiency caused by mutations in the PHKG2 geneDeeksha S Bali, Jennifer L Goldstein, Keri Fredrickson, et al.
American Journal of Obstetrics and Gynecology|February 5, 2008
Pregnancies in glycogen storage disease type IaDaniëlle H J Martens, Jan Peter Rake, Martin Schwarz, et al.
Hepatology Communications|November 9, 2019
Liver Glycogen Phosphorylase Deficiency Leads to Profibrogenic Phenotype in a Murine Model of Glycogen Storage Disease Type VILane H Wilson, Jun-Ho Cho, Ana Estrella, et al.
Journal of Inherited Metabolic Disease|May 27, 2018
Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type IaYoung Mok Lee, Thomas J Conlon, Andrew Specht, et al.
JIMD Reports|August 26, 2015
Safety and Efficacy of Chronic Extended Release Cornstarch Therapy for Glycogen Storage Disease Type IKatalin M Ross, Laurie M Brown, Michelle M Corrado, et al.
Journal of Inherited Metabolic Disease|August 16, 2019
Cornstarch requirements of the adult glycogen storage disease Ia population: A retrospective reviewKathryn R Dahlberg, Iris A Ferrecchia, Monika Dambska-Williams, et al.
Molecular Therapy. Methods & Clinical Development|September 16, 2024
Validation of high-sensitivity assays to quantitate cerebrospinal fluid and serum β-galactosidase activity in patients with GM1-gangliosidosisKaren J Quadrini, Catherine Vrentas, Christian Duke, et al.
Biochemical and Biophysical Research Communications|January 26, 2020
Glucose-6-phosphate transporter mediates macrophage proliferation and functions by regulating glycolysis and mitochondrial respirationEek Hyung Jeon, Tae Sub Park, Yuyeon Jang, et al.
Journal of Inherited Metabolic Disease|April 12, 2017
Clinical and biochemical heterogeneity between patients with glycogen storage disease type IA: the added value of CUSUM for metabolic controlFabian Peeks, Thomas A H Steunenberg, Foekje de Boer, et al.
Journal of Health Economics and Outcomes Research|February 16, 2026
Trial Interviews to Explore Glycogen Storage Disease Type Ia Patient Experiences Following Gene TherapyDiane M Turner-Bowker, Jessica Butler, Shayna Egan, et al.
Pageof 10